Pembrolizumab as adjuvant therapy in non-small-cell lung cancer

Lancet Oncol. 2022 Dec;23(12):e527. doi: 10.1016/S1470-2045(22)00636-2.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized / adverse effects
  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • Combined Modality Therapy
  • Humans
  • Lung Neoplasms* / drug therapy

Substances

  • pembrolizumab
  • Antibodies, Monoclonal, Humanized